Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

Jonathan H Schatz, Elisa Oricchio, Andrew L. Wolfe, Man Jiang, Irina Linkov, Jocelyn Maragulia, Weiji Shi, Zhigang Zhang, Vinagolu K. Rajasekhar, Nen C. Pagano, John A. Porco, Julie Teruya-Feldstein, Neal Rosen, Andrew D. Zelenetz, Jerry Pelletier, Hans Guido Wendel

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

New anticancer drugs that target oncogenic signaling molecules have greatly improved the treatment of certain cancers. However, resistance to targeted therapeutics is a major clinical problem and the redundancy of oncogenic signaling pathways provides back-up mechanisms that allow cancer cells to escape. For example, the AKT and PIM kinases produce parallel oncogenic signals and share many molecular targets, including activators of cap-dependent translation. Here, we show that PIM kinase expression can affect the clinical outcome of lymphoma chemotherapy. We observe the same in animal lymphoma models. Whereas chemoresistance caused by AKT is readily reversed with rapamycin, PIM-mediated resistance is refractory to mTORC1 inhibition. However, both PIM- and AKT-expressing lymphomas depend on cap-dependent translation, and genetic or pharmacological blockade of the translation initiation complex is highly effective against these tumors. The therapeutic effect of blocking cap-dependent translation is mediated, at least in part, by decreased production of short-lived oncoproteins including c-MYC, Cyclin D1, MCL1, and the PIM1/2 kinases themselves. Hence, targeting the convergence of oncogenic survival signals on translation initiation is an effective alternative to combinations of kinase inhibitors.

Original languageEnglish (US)
Pages (from-to)1799-1807
Number of pages9
JournalJournal of Experimental Medicine
Volume208
Issue number9
DOIs
StatePublished - Aug 29 2011
Externally publishedYes

Fingerprint

Lymphoma
Phosphotransferases
Neoplasms
Oncogene Proteins
Cyclin D1
Protein Biosynthesis
Therapeutic Uses
Sirolimus
Animal Models
Pharmacology
Drug Therapy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. / Schatz, Jonathan H; Oricchio, Elisa; Wolfe, Andrew L.; Jiang, Man; Linkov, Irina; Maragulia, Jocelyn; Shi, Weiji; Zhang, Zhigang; Rajasekhar, Vinagolu K.; Pagano, Nen C.; Porco, John A.; Teruya-Feldstein, Julie; Rosen, Neal; Zelenetz, Andrew D.; Pelletier, Jerry; Wendel, Hans Guido.

In: Journal of Experimental Medicine, Vol. 208, No. 9, 29.08.2011, p. 1799-1807.

Research output: Contribution to journalArticle

Schatz, JH, Oricchio, E, Wolfe, AL, Jiang, M, Linkov, I, Maragulia, J, Shi, W, Zhang, Z, Rajasekhar, VK, Pagano, NC, Porco, JA, Teruya-Feldstein, J, Rosen, N, Zelenetz, AD, Pelletier, J & Wendel, HG 2011, 'Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma', Journal of Experimental Medicine, vol. 208, no. 9, pp. 1799-1807. https://doi.org/10.1084/jem.20110846
Schatz, Jonathan H ; Oricchio, Elisa ; Wolfe, Andrew L. ; Jiang, Man ; Linkov, Irina ; Maragulia, Jocelyn ; Shi, Weiji ; Zhang, Zhigang ; Rajasekhar, Vinagolu K. ; Pagano, Nen C. ; Porco, John A. ; Teruya-Feldstein, Julie ; Rosen, Neal ; Zelenetz, Andrew D. ; Pelletier, Jerry ; Wendel, Hans Guido. / Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. In: Journal of Experimental Medicine. 2011 ; Vol. 208, No. 9. pp. 1799-1807.
@article{16c36cf3ca4f424489638be49ecd1422,
title = "Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma",
abstract = "New anticancer drugs that target oncogenic signaling molecules have greatly improved the treatment of certain cancers. However, resistance to targeted therapeutics is a major clinical problem and the redundancy of oncogenic signaling pathways provides back-up mechanisms that allow cancer cells to escape. For example, the AKT and PIM kinases produce parallel oncogenic signals and share many molecular targets, including activators of cap-dependent translation. Here, we show that PIM kinase expression can affect the clinical outcome of lymphoma chemotherapy. We observe the same in animal lymphoma models. Whereas chemoresistance caused by AKT is readily reversed with rapamycin, PIM-mediated resistance is refractory to mTORC1 inhibition. However, both PIM- and AKT-expressing lymphomas depend on cap-dependent translation, and genetic or pharmacological blockade of the translation initiation complex is highly effective against these tumors. The therapeutic effect of blocking cap-dependent translation is mediated, at least in part, by decreased production of short-lived oncoproteins including c-MYC, Cyclin D1, MCL1, and the PIM1/2 kinases themselves. Hence, targeting the convergence of oncogenic survival signals on translation initiation is an effective alternative to combinations of kinase inhibitors.",
author = "Schatz, {Jonathan H} and Elisa Oricchio and Wolfe, {Andrew L.} and Man Jiang and Irina Linkov and Jocelyn Maragulia and Weiji Shi and Zhigang Zhang and Rajasekhar, {Vinagolu K.} and Pagano, {Nen C.} and Porco, {John A.} and Julie Teruya-Feldstein and Neal Rosen and Zelenetz, {Andrew D.} and Jerry Pelletier and Wendel, {Hans Guido}",
year = "2011",
month = "8",
day = "29",
doi = "10.1084/jem.20110846",
language = "English (US)",
volume = "208",
pages = "1799--1807",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "9",

}

TY - JOUR

T1 - Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

AU - Schatz, Jonathan H

AU - Oricchio, Elisa

AU - Wolfe, Andrew L.

AU - Jiang, Man

AU - Linkov, Irina

AU - Maragulia, Jocelyn

AU - Shi, Weiji

AU - Zhang, Zhigang

AU - Rajasekhar, Vinagolu K.

AU - Pagano, Nen C.

AU - Porco, John A.

AU - Teruya-Feldstein, Julie

AU - Rosen, Neal

AU - Zelenetz, Andrew D.

AU - Pelletier, Jerry

AU - Wendel, Hans Guido

PY - 2011/8/29

Y1 - 2011/8/29

N2 - New anticancer drugs that target oncogenic signaling molecules have greatly improved the treatment of certain cancers. However, resistance to targeted therapeutics is a major clinical problem and the redundancy of oncogenic signaling pathways provides back-up mechanisms that allow cancer cells to escape. For example, the AKT and PIM kinases produce parallel oncogenic signals and share many molecular targets, including activators of cap-dependent translation. Here, we show that PIM kinase expression can affect the clinical outcome of lymphoma chemotherapy. We observe the same in animal lymphoma models. Whereas chemoresistance caused by AKT is readily reversed with rapamycin, PIM-mediated resistance is refractory to mTORC1 inhibition. However, both PIM- and AKT-expressing lymphomas depend on cap-dependent translation, and genetic or pharmacological blockade of the translation initiation complex is highly effective against these tumors. The therapeutic effect of blocking cap-dependent translation is mediated, at least in part, by decreased production of short-lived oncoproteins including c-MYC, Cyclin D1, MCL1, and the PIM1/2 kinases themselves. Hence, targeting the convergence of oncogenic survival signals on translation initiation is an effective alternative to combinations of kinase inhibitors.

AB - New anticancer drugs that target oncogenic signaling molecules have greatly improved the treatment of certain cancers. However, resistance to targeted therapeutics is a major clinical problem and the redundancy of oncogenic signaling pathways provides back-up mechanisms that allow cancer cells to escape. For example, the AKT and PIM kinases produce parallel oncogenic signals and share many molecular targets, including activators of cap-dependent translation. Here, we show that PIM kinase expression can affect the clinical outcome of lymphoma chemotherapy. We observe the same in animal lymphoma models. Whereas chemoresistance caused by AKT is readily reversed with rapamycin, PIM-mediated resistance is refractory to mTORC1 inhibition. However, both PIM- and AKT-expressing lymphomas depend on cap-dependent translation, and genetic or pharmacological blockade of the translation initiation complex is highly effective against these tumors. The therapeutic effect of blocking cap-dependent translation is mediated, at least in part, by decreased production of short-lived oncoproteins including c-MYC, Cyclin D1, MCL1, and the PIM1/2 kinases themselves. Hence, targeting the convergence of oncogenic survival signals on translation initiation is an effective alternative to combinations of kinase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=80054845323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054845323&partnerID=8YFLogxK

U2 - 10.1084/jem.20110846

DO - 10.1084/jem.20110846

M3 - Article

C2 - 21859846

AN - SCOPUS:80054845323

VL - 208

SP - 1799

EP - 1807

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 9

ER -